EICHOR
● Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Condition: Advanced Renal Cell Carcinoma (RCC) · Sponsor: Bristol-Myers Squibb
About this study
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
This description comes directly from the study's public registry record.
Talk to the study team
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
Locations (91)
| Local Institution - 0178 | Palo Alto, California, United States | Not Yet Recruiting |
| Local Institution - 0117 | New Haven, Connecticut, United States | Not Yet Recruiting |
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Local Institution - 0177 | Miami, Florida, United States | Not Yet Recruiting |
| Local Institution - 0126 | Orlando, Florida, United States | Not Yet Recruiting |
| Local Institution - 0175 | Atlanta, Georgia, United States | Not Yet Recruiting |
| Local Institution - 0170 | Fort Wayne, Indiana, United States | Not Yet Recruiting |
| Local Institution - 0124 | Iowa City, Iowa, United States | Not Yet Recruiting |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
| Local Institution - 0176 | Big Rapids, Michigan, United States | Not Yet Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | Hauppauge, New York, United States | Recruiting |
+ 79 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.